



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 473/02, 513/04, 471/04, A61K 31/505, 31/52		A1	(11) International Publication Number: WO 98/52948 (43) International Publication Date: 26 November 1998 (26.11.98)
(21) International Application Number: PCT/US98/09964		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 18 May 1998 (18.05.98)			
(30) Priority Data: 08/858,778 19 May 1997 (19.05.97) US			
(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 5th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).			
(72) Inventors: CARSON, Dennis, A.; 14824 Vista Del Oceano, Del Mar, CA 92014 (US). COTTAM, Howard; 208 White Horse Lane, Fallbrook, CA 92028 (US).			
(74) Agent: BERLINER, Robert; Fulbright & Jaworski L.L.P., 29th floor, 865 S. Figueroa Street, Los Angeles, CA 90017-2571 (US).			

(54) Title: COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION

(57) Abstract

Novel, heterocyclic compounds having at least one ring nitrogen, disclosed side chains and, in some embodiments, an oxygen *ortho* to the ring nitrogen inhibit inflammatory responses associated with TNF- α and fibroblast proliferation *in vivo* and *in vitro*. The compounds of the invention neither appreciably inhibit the activity of cAMP phosphodiesterase nor the hydrolysis of phosphatidic acid, and are neither cytotoxic nor cytostatic. Preferred compounds of the invention are esters. Methods for the use of the novel compounds to inhibit ceramide-mediated intracellular responses in stimuli *in vivo* (particularly TN- α) are also described. The methods are expected to be of use in reducing inflammatory responses (for example, after angioplasty), in limiting fibrosis (for example, of the liver in cirrhosis), in inhibiting cell senescence, cell apoptosis and UV induced cutaneous immune suppression. Compounds having enhanced water solubility are also described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED
SIGNAL TRANSDUCTION

5

RELATED PATENT APPLICATIONS

This application is a continuation-in-part of US Patent Application Serial Number 08/367,102, filed December 29, 1994 and a continuation-in-part of US Patent Application Serial Number 08/482,551, filed June 7, 1995.

10

STATEMENT OF GOVERNMENT SUPPORT

This invention may have been made with government support under Grant No. GM-23200 awarded by the National Institutes of Health. The government may have certain 15 rights in the invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention.

The invention relates to compounds effective in 20 modulating cellular responses stimulated by ceramide-mediated signal transduction, in particular in response to stimulus by the cytokine tumor necrosis factor α (TNF- α). More specifically, it relates to compounds which inhibit the development of conditions associated with 25 cell stimulus through the ceramide-mediated signal transduction pathway.

2. History of the Prior Art.

The sphingomyelin pathway is a cellular signal transduction pathway that is believed to be involved in 30 mediating cellular responses to several cytokines (including TNF- α and IL- 1 β) and growth factors (e.g., platelet derived growth factor and fibroblast growth factor) (see, e.g., Dressler, et al., *Science*, 259:1715-1718, 1992; and, Jacobs and Kester, *Amer.J.Physiol.*, 265: 35 740-747, 1993). It is believed that interaction of such molecules with cell surface receptors triggers activation of a plasma membrane sphingomyelinase. Sphingomyelinase

in turn catalyzes the hydrolysis of sphingomyelin to ceramide and phosphocholine. Ceramide is believed to act as a second messenger through activation of a proline-directed, serine/threonine kinase (ceramide-activated 5 protein kinase or "CaPK"). Ceramide also interacts with MAP kinase and protein kinase C zeta (see, e.g., Rivas, et al., *Blood*, 83:2191-2197, 1993) and with a serine/threonine protein phosphatase (see, Hannun, et al., *TIBS*, 20:73-77, 1995).

10 Recent investigation has provided evidence that the sphingomyelin pathway may mediate cellular senescence and apoptosis (programmed cell death) in response to TNF- α (see, e.g., Jayadev, et al., *J.Biol.Chem.*, 270:2047-2052, 1994; and, Dbaibo, et al., *J.Biol.Chem.*, 268:17762-17766, 15 1993) and radiation (Haimovitz-Friedman, et al., *J.Exp.Med.*, 180:525-535, 1994). In this respect, ceramide has been presumed to mimic the effects of TNF- α on intracellular processes.

SUMMARY OF THE INVENTION

The invention is directed toward the development and use of compounds to inhibit cellular responses to ceramide metabolites of the sphingomyelin signal transduction pathway, such as inflammation, fibrosis, ultraviolet light induced cutaneous immune suppression, cell senescence and apoptosis.

In one aspect, the invention consists of novel compounds comprised of heterocyclic molecules with biologically active side chains (the "compounds of the invention"). Purine, pteridine, thiadiazolopyrimidine, quinalozine and isoquinolone based compounds are included in the invention. Particularly preferred among these compounds are those which have enhanced water solubility; e.g., morpholinoethyl esters of the compounds of the invention.

The compounds of the invention do not inhibit the activity of cAMP phosphodiesterase and therefore do not pose the risk of side-effects associated with other TNF- α inhibitors (e.g., pentoxifylline), such as sleeplessness and anxiety. Indeed, surprisingly, one of the more potent TNF- α activity inhibitors among the compounds of the invention (compound 37) had the least inhibitory effect on phosphodiesterase type IV, the predominant phosphodiesterase isoenzyme in monocytes and neutrophils. This is due to the fact that compounds such as 37 do not have a methylxanthine structure. Many common phosphodiesterase inhibitors (such as theophylline, theobromine, and caffeine) are methylxanthine compounds.

Moreover, all of the compounds of the invention inhibit apoptosis and retard cellular responses to TNF- α *in vitro* and *in vivo* with greater potency than pentoxifylline. Unexpectedly, the potency of at least the non-isoquinolone compounds appears to be dependent in part on the presence of ring nitrogens (other than the pyrimidine nitrogens), suggesting that binding to the target receptor responsible for inhibition of the

activity of TNF- α observed is also regulated to some extent by the presence of such ring nitrogens. Further, the effects of all of the compounds appear to be totally unrelated to phosphodiesterase inhibition. This is 5 particularly interesting given that increases in cAMP levels in cells can induce apoptosis in B cells (see, e.g., Lømo, et al., *J. Immunol.*, 154:1634-1643, 1995).

Recently, studies have shown (see, e.g. Verheij, et al., *Nature*, 380:75-79, 1996) that ceramide initiates 10 apoptosis through the stress-activated protein kinase (SAPK/JNK) pathway. Thus, cells exposed to stresses such as ionizing radiation, hydrogen peroxide, UV-C radiation, heat shock, and TNF- α , or to C-2 ceramide, acquired biochemical and morphological features typical of 15 apoptosis. Indeed, these stresses have been shown to increase cellular levels of ceramide. Moreover, the role of one of the stress-activated protein kinases, c-jun (referred to as Jun kinase or JNK) in apoptosis was confirmed following stress and C-2 ceramide exposure. In 20 this regard, compounds of the invention, particularly the isoquinolines, have shown activity as inhibitors of Jun kinase activation induced by anisomycin (a non-specific protein synthesis inhibitor) in MOLT-4 human lymphoblastoid cells or by LPS in RAW mouse macrophages. 25 Therefore, a possible mechanism of activity of these compounds is the inhibition of one arm of the stress response pathway involving a Jun kinase in response to stress or to ceramide.


Another aspect of the invention consists of methods 30 for the use of the novel compounds in inhibiting ceramide-activated cellular responses to stimuli, in particular stimuli for cell senescence and apoptosis. This aspect of the invention has potential therapeutic significance in the treatment of cell death associated 35 conditions such as stroke, cardiac ischemia, nerve damage and Alzheimer's disease.

Another aspect of the invention consists of methods which exploit the ability of the compounds of the invention to absorb UV radiation. This aspect of the invention has potential therapeutic significance in the 5 treatment and prevention of radiation dermatoses, including those associated with therapeutic regimes for treatment of cancer.

The compounds of the invention are expected to be particularly useful in reducing the effects of aging in 10 skin as well as the onset and progression of radiation dermatitis.

In another aspect, the invention features a compound having the formula:

15



where

20 R_1 is a terminally substituted normal alkyl having from 1 to 7 carbon atoms, a terminally substituted alkenyl having from 2 to 7 carbon atoms, a terminally substituted ether having from 2 to 6 carbon atoms, a terminally substituted secondary amine having from 2 to 6 25 carbon atoms, or substituted aryl having less than 8 carbons, where said terminal group is NH_2 , substituted amino, acyloxy, SO_3H , PO_4H_2 , $NNO(OH)$, SO_2NH_2 , $PO(OH)NH_2$, SO_2R or $COOR$, where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, 30 tetrazolyl, benzyl, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is NH_2 or a substituted amino where the substituents on the amino have 1 to 6 carbon atoms, one of which can be replaced by an oxygen atom or nitrogen atom;

35 Z is C, CH, or N;

R_2 is an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms when

Z is C, R₂ is a halogen, NO, amino, or substituted amino when Z is CH, or R₂ is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms when Z is N;

5 A is CO when Z is N, or CR₅ when Z is C or CH, where R₅ is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, aryl or aralkyl having less than 7 carbon atoms, OH, or an O-alkyl having from 1 to 5 carbon atoms and there is a double bond between Z and A when Z is C and a
10 single bond between Z and A when Z is CH;

Y₁ is N, NR₆, or CR₆, where R₆ is H, NO, an amino, a substituted amino, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms;


15 Y₂ is N or CH; and

X is S when Y₁ and Y₂ are N, CR₇, when Y₁ is NR₆ where R₇ is H, OH, SH, Br, Cl, or I, or =C(R₃)-C(R₄)= when Y₁ is N, CH or CR₆ and Y₂ is N or CH, where each of R₃ and R₄, independently, is H, an alkyl, a cyclic alkyl, a

20 heterocyclic alkyl, alkenyl, aryl, alkylcarboxyl, or aralkyl having less than 7 carbon atoms, SH, OH or an O-alkyl having from 1 to 5 carbon atoms,
or a salt thereof.

In another aspect, the invention features a compound
25 having the formula:


30



where Q is a halogen or substituted amino, R₂ is a halogen, NO, an amino, or a substituted amino, R₃ is SH or OH, R₄ is SH or OH, R₅ is H, an alkyl, a cyclic alkyl, a 5 heterocyclic alkyl, alkenyl, aryl or aralkyl having less than 7 carbon atoms, OH, or an O-alkyl having from 1 to 5 carbon atoms, and R₆ is NO, an amino, or a substituted amino,

or a salt thereof.

10 In preferred embodiments, the compound has the formula: $\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2\text{C}_6\text{H}_4\text{CH}_2\text{CH}_2\text{C}_6\text{H}_5$.



Preferably, R_1 is a terminally substituted normal alkyl having from 1 to 7 carbon atoms, where said terminal group and is NH_2 , substituted amino, or $COOR$, where R is H, an alkyl having from 1 to 4 carbon atoms, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is a substituted amino where the substituents on the amino have 1 to 6 carbon atoms, one of which can be replaced by an oxygen atom or nitrogen atom; R_2 , when present, is an alkyl having less than 7 carbon atoms (i.e., Me, or $-(CH_2)_2CH_3$); each of R_3 and R_4 , independently, is H, SH, OH, an alkyl, aryl, alkylcarboxyl, or aralkyl having less than 7 carbon atoms, or an O-alkyl having from 1 to 5 carbon atoms; and R_6 is NO, an amino, or a substituted amino (i.e., NHR , or NR_2 , where R is H, an alkyl having from 1 to 4 carbon atoms, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is a substituted amino where the substituents on the amino have 1 to 6 carbon atoms, one of which can be replaced by an oxygen atom or nitrogen atom).


atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl, benzyl, an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is NH_2 or a substituted amino where the substituents on the amino

5 have 1 to 6 carbon atoms, one of which can be replaced by an oxygen atom or nitrogen atom, aryl, or substituted aryl, where the substituted aryl has one, two, or three substituents including halogens or alkyls having 1 to 4 carbons). More preferably, R_1 is a terminally substituted

10 normal alkyl having from 1 to 4 carbon atoms where said terminal group is COOR where R is an N-morpholinoalkyl group (i.e., an N-morpholinoethyl group), and each of R_3 and R_4 , independently, is an O-alkyl having from 1 to 5 carbon atoms.

15 Most preferably, R_1 is $-(\text{CH}_2)_3\text{COOR}$ where R is an N-morpholinoethyl group, and R_3 and R_4 each are H or methoxy groups, thus providing the compounds with enhanced water solubility.

In other preferred embodiments, the compound has the
20 formula:



where

R_1 is a terminally substituted normal alkyl having from 1 to 7 carbon atoms, a terminally substituted

30 alkenyl having from 2 to 7 carbon atoms, a terminally substituted ether having from 2 to 6 carbon atoms, a terminally substituted secondary amine having from 2 to 6 carbon atoms, or substituted aryl having less than 8 carbons, where said terminal group is NH_2 , substituted

35 amino, acyloxy, SO_3H , PO_4H_2 , $\text{NNO}(\text{OH})$, SO_2NH_2 , $\text{PO}(\text{OH})\text{NH}_2$, SO_2R or COOR , where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms,

tetrazolyl, benzyl, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is NH₂ or a substituted amino where the substituents on the amino have 1 to 6 carbon atoms, one of which can be replaced by

5 an oxygen atom or nitrogen atom;

R₂ is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms;

Y₂ is N or CH;

10 R₆ is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms; and

R₇ is H, OH, SH, Br, Cl, or I,
or a salt thereof.

15 Further advantages and embodiments of the invention included therein will become apparent from the following disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

20 FIGURE 1 is a bar graph depicting inhibition of cell growth arrest in 3T3 fibroblasts according to the invention after growth arrest was induced through deprivation of the cells of serum. The cells were incubated and grown to 90% confluence in serum. The 25 medium was then removed and replaced with serum-free medium. To assess the effect of an inventive compound (no. 37, a pteridine) on cell senescence in the presence of ceramide, aliquots of the cells were incubated with different concentrations of each. Concentrations of 30 compound no. 37 are indicated by the insert legend while concentrations of ceramide are indicated along the x axis. Inhibitory effects were assessed as a measure of DNA synthesis; [³H] thymidine incorporation detection is indicated along the y axis.

35 FIGURE 2 is a bar graph depicting inhibition of cell apoptosis in human (Jurkat) T lymphocytes according to the invention. The inhibitory activity of two inventive

compounds (nos. 37 and 6 (a purine)) was tested in comparison to like activity of pentoxyfilline and a control compound, Ro 20-1724. Activation of the sphingomyelin signal transduction pathway was stimulated 5 by incubation of the cells with an anti-FAS monoclonal antibody (which binds CD95, a cell surface receptor which triggers cell apoptosis). Percent inhibition was measured as a function of the number of cells which excluded vital dye erythrosin B. Percent inhibition is 10 indicated along the y axis while the concentration of compounds tested is indicated along the x axis.

FIGURE 3 is a bar graph depicting inhibition of activity on the part of CaPK in Jurkat cells according to the invention. The inhibitory activity of a compound of 15 the invention (no. 37) was tested in the presence of either ceramide or anti-FAS. Inhibition of CaPK activity was measured as a function of phosphorylation and detected by autoradiography. The compounds the cells were incubated in are indicated along the y axis while 20 the percent control (i.e., inhibition of CaPK) is indicated along the x axis. Shorter bars indicate greater relative inhibition.

FIGURES 4 (a)-(g) are copies of spectrographs indicative of absorbance of inventive compounds no. 37, 25 no. 6, no. 37 in combination with no. 6, oxo variants of nos. 37 and 6, as well as, for comparison, PABA (p-amino benzoic acid, a common sunscreen additive) and isoquinolone. The inventive compounds absorbed through most of the UVB wavelength, while a mixture of compound 30 nos. 37 and 6 absorbed throughout the UVB wavelength.

FIGURES 5(a) and (b) depict, respectively, the results of an enzyme-linked immunosorbent assay (ELISA) for TNF- α production by bacterial lipopolysaccharide (endotoxin) stimulated human monocytes incubated with the 35 compounds of the invention and a control compound (Ro-1724, that is a known and specific inhibitor of phosphodiesterase type IV [the predominant isoform of

phosphodiesterase found in monocytes and neutrophils)). Compounds tested are identified by the number assigned to them in Table 1. The horizontal axis of each graph shows the amount of each compound tested (in μ M) while the 5 vertical axis shows the IC_{50} values for TNF- α production as a percentage of the production in the presence of only the control compound.

FIGURE 6 is a bar graph depicting the results of an ELISA assay for inhibition of the activity of 10 phosphodiesterase type IV by the control compound (Ro 20-1724) and several of the inventive compounds. The horizontal axis identifies the degree of inhibition achieved in pmol substrate/minutes of contact/mg of phosphodiesterase type IV. The amounts of each compound 15 tested are identified along the vertical axis. Compounds tested are identified by the number assigned to them in Table 1.

FIGURE 7 is a graph depicting the results of an assay for in vivo leukopenia in mouse blood in response 20 to lipopolysaccharide (LPS). Leukopenia induced by LPS is mediated by TNF. Hence, this model assesses both TNF production and action. Compounds tested for inhibition 25 of leukopenia are identified by the number assigned to them in Table 1. Along the x axis of the graph, the numbers correspond to the number of white blood cells detected as cells/ml of fluid. The results (shown by bars) are expressed in terms of a percentage of the leukopenia response (based on neutrophil content) to pure LPS, in absence of other compounds.

30 FIGURE 8 depicts the results of an assay for inhibition by compounds of the invention (nos. 37 and 6) of the effects of a cell permeable ceramide analog (C_2 - ceramide), dihydro ceramide and diacyl glycerol on TNF- α production by human monocytes. Inhibition of TNF- α 35 production was measured by ELISA; the results are indicated in pg/ml of TNF- α along the x axis.

FIGURE 9 depicts the results of an assay for inhibition by a compound of the invention (no. 37) to prevent the stimulatory effects of C₂ - ceramide or protein kinase C activity in human lymphocyte extracts.

5 Inhibitory effects were assessed as a measure of DNA synthesis; [³H] thymidine incorporation detection is indicated along the y axis.

FIGURE 10 depicts the results of an assay for in vitro TNF- α production by human macrophages in response 10 to lipopolysaccharide (LPS) and inhibition of that production by pteridine and isoquinolone compounds of the invention (nos. 37 and 11-49). Along the x axis of the graph, the numbers correspond to the concentration of TNF- α detected in pg/ml.

15 FIGURE 11 depicts inhibition of PDGF induced fibroblast proliferation among 3T3 fibroblasts in response to the inventive compounds. The compounds tested are identified along the x axis by the numbers assigned to them in Table 1. Inhibitory effects were 20 assessed as a measure of DNA synthesis; [³H] thymidine incorporation detection is indicated along the y axis.

FIGURE 12 depicts inhibition of EGF induced fibroblast proliferation among 3T3 fibroblasts in response to the inventive compounds. The compounds 25 tested are identified along the x axis by the numbers assigned to them in Table 1. Inhibitory effects were assessed as a measure of DNA synthesis; [³H] thymidine incorporation detection is indicated along the y axis.

FIGURE 13 depicts data indicative of the apoptotic 30 protective characteristics of the compounds of the invention as represented by compounds 1C-261 (Compound 37) and 11-49. Human lymphocytes were cultured in serum aliquots with the concentrations of the inventive compounds indicated along the x axis of the FIGURE. 35 Protective effects were measured over 4 days as a function of the length of survival of the cultured cells in the presence of the inventive compounds as compared to

survival of the cells in the absence of the inventive compounds. 100% survival (y axis) means that a number of treated cells all survived throughout the test period while an equal number of untreated cells died.

5 FIGURES 14(a) through (c) show the structure of commercially available isoquinoline structures whose inhibitory effect with respect to production of TNF- α by human monocytes prior to modification to add side chain substituents according to the invention was tested.

10 Except for Compound S52,626-6 (6,7-dimethoxy- 1(2H)-isoquinoline, which possessed mild inhibitory activity as shown in FIGURE 10) none of the tested compounds possessed any such inhibitory activity prior to their modification according to the invention, even at

15 concentrations up to 500 μ M.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. Compounds of the Invention.

The compounds of the invention generally comprise

20 purines, pteridines, thiadiazolopyrimidines and quinazolines prepared according to the schemes described below. For reference, the techniques used in synthesizing the compounds are adaptations of the well-known Traube Synthesis protocol (Lister, "Purines" (Wiley-Interscience, 1971), at p. 220), beginning with 4,5-diaminopyrimidines; to wit: (1) for the purines in general, see Brown, "The Chemistry of Heterocyclic Compounds: Fused Pyrimidines", Part II, The Purines, 1971), at pp. 31-90; (2) for the 9-dieazapurines in

25 particular, see Fox, et al., J. Org. Chem., 43:2536, 1978; (3) for the pteridines, see, for a description of the standard Timmis reaction, Nishigaki, et al., *Heterocycles*, 15:757-759, 1981; Timmis, *Nature*, 164:13 9, 1949, (or other standard Traube-like protocols for

30 preparing pteridines by ring closure of diamino-

35 pyrimidines using a two carbon reagent); and, (4) for the

pyrimidines, see, Schrage and Hitchings, *J. Org. Chem.*, 16:207, 1951.

Compounds of the invention, intermediates and compounds tested for comparison of activity to the 5 compounds of the invention are identified in the discussion below by the numbers assigned to each compound in Table 1.

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type		mp(°C)	formula	analyses ^a	TNF α IC ₅₀ ^b
1	I		102-103			85
2	I		208-210			>200
4	I		162-165	$C_{11}H_{14}N_4O_4$	C_6H_5N	200
5	I		76-78	$C_{12}H_{16}N_4O_4$	HRMS	10

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type		mp(°C)	formula	analyses ^a	TNF α IIC ₅₀ ^b
6	I	<chem>CC(C)(C)OC(=O)c1c(C(=O)N(C)C)c2c(N)ncnc2n1</chem>	73-75	C ₁₃ H ₁₈ N ₄ O ₄	C,H,N	6
7	I	<chem>CC(C)(C)OC(=O)c1c(C(=O)N(C)C)c2c(N)ncnc2n1</chem>	84-85	C ₁₄ H ₂₀ N ₄ O ₄	C,H,N	11
8	I	<chem>CC(C)(C)OC(=O)c1c(C(=O)N(C)C)c2c(N)ncnc2n1</chem>	158-160	C ₁₆ H ₁₆ N ₄ O ₄	C,H,N	>200
10	I	<chem>CC(C)(C)OC(=O)c1c(C(=O)N(C)C)c2c(N)ncnc2n1</chem>	101-102	C ₁₃ H ₁₇ BrN ₄ O ₄	C,H,N	60

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type		mp(°C)	formula	analyses ^a	TNF α IC ₅₀ ^b
11	I		218-219	C ₁₆ H ₁₅ BrN ₄ O ₄	C, H, N	>200
12	I		202-206	C ₁₃ H ₁₈ N ₄ O ₄ S	C, H, N	100
13	I		>293 dec	C ₁₇ H ₁₈ N ₄ O ₄ S	C, H, N	>200
20	II		>218 dec	C ₁₂ H ₂₀ N ₄ O ₃	C, H, N	ND ^c

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type		mp(°C)	formula	analyses ^a	TNF α IC ₅₀ ^b
24	I		>295 dec	C ₁₂ H ₁₈ N ₄ O ₃	C, H, N	50
25	I		>320			>200
31	I		oil	C ₁₅ H ₂₂ N ₄ O ₄	C, H, N	5
33	II		>270 dec	C ₅ H ₈ N ₄ O ₂	C, H, N	ND

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type		mp(°C)	formula	analyses ^a	TNF α I C_{50} ^b
34	II		287-289	C ₇ H ₆ N ₄ O ₂	C, H, N	ND
35	II		187-189	C ₉ H ₁₀ N ₄ O ₄	C, H, N	ND
36	II		90-92	C ₁₃ H ₁₆ N ₄ O ₄	C, H, N	12
36a	II		199-202	C ₁₁ H ₁₂ N ₄ O ₄	C, H, N	>200

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type		mp(°C)	formula	analyses ^a	TNF α IC ₅₀ ^b
37	II		53-55	C ₁₅ H ₂₀ N ₄ O ₄	C, H, N	5
37a	II		97-99	C ₁₃ H ₁₆ N ₄ O ₄	C, H, N	>200
38	II		118-119	C ₁₂ H ₁₂ N ₄ O ₄	HRMS	25
39	II		92-95	C ₁₇ H ₂₂ N ₄ O ₆	C, H, N	ND

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type		mp(°C)	formula	analyses ^a	TNF α IC ₅₀ ^b
40	II		218-222	C ₁₁ H ₁₄ N ₄ O ₂	C, H, N	ND
41	II		66-68	C ₁₇ H ₂₄ N ₄ O ₄	C, H, N	130
41a	II		161-162	C ₁₅ H ₂₀ N ₄ O ₄	C, H, N	ND
42	II		>307 dec	C ₁₃ H ₁₀ N ₄ O ₄	N/A	ND

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type		mp(°C)	formula	analyses ^a	TNF α IC ₅₀ ^b
43a	II		N/A	N/A	N/A	N/A
43b	II		N/A	N/A	N/A	N/A
43c	II		N/A	N/A	N/A	N/A
43d	II		N/A	N/A	N/A	N/A

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type		mp(°C)	formula	analyses ^a	TNF α /IC ₅₀ ^b
43e	II		N/A		HRMS N/A	
43	II		99-100	C ₁₉ H ₂₀ N ₄ O ₄	HRMS >200	
44	III		73-75	C ₁₂ H ₁₈ N ₄ O ₂ S	C ₆ H ₅ N 75	
45	III		210-213	C ₅ H ₄ N ₄ O ₂ S	C ₆ H ₅ N ND	

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data

Comp	Type	mp(°C)	formula	analyses ^a	TNF α IC ₅₀ ^b
46	III	142-144	C ₇ H ₈ N ₄ O ₂ S	C ₇ H ₈ N	ND
47	III	45-47	C ₁₁ H ₁₄ N ₄ O ₄ S	C ₁₁ H ₁₄ N	25
47a	III	121-122	C ₉ H ₁₀ N ₄ O ₄ S	HRMS	>200
48	III	oil	C ₁₃ H ₁₈ N ₂ O ₃	C ₁₃ H ₁₈ N	18

TABLE 1
Physicochemical Data for all New Compounds and TNF- α Inhibition Data


Comp	Type	Structure	mp(°C)	formula	analyses ^a	TNF α IC ₅₀ ^b
51	IV		oil	C ₁₄ H ₂₀ N ₄ O ₃	C, H, N ^f	ND
52	IV		oil	C ₁₅ H ₁₈ N ₂ O ₄	C, H, N ^g	55
52a	IV		163-165	C ₁₃ H ₁₄ N ₂ O ₄	C, H, N	>200

^aAll compounds analyzed for C, H, N or by exact mass high resolution mass spectrometry; results were within $\pm 0.4\%$ of theoretical values. ^bConcentration of compound in μM which inhibited the product of TNF α by 50% of control. ^cND = not determined. ^dC: calc'd, 58.61; found 59.22. ^eH: calc'd, 4.13; found 3.70. ^fN: calc'd, 10.25; found 9.77. ^gC: calc'd, 59.62; found, 60.61. Compound types are: I=purines; II=pteridines; III=thiadiazolopyrimidines; IV=quinoxalines; and, V=isoquinolones. "N/A" means data not available (but can be obtained through conventional analysis techniques).

B. Purine synthesis.

The purines of the invention have the general formula (I):

5



where Z is N or CH;

R₁ is (CH₂)_nA, where:

10 A is NH₂, acyloxy, SO₃H, PO₄H₂, NNO(OH), SO₂NH₂, PO(OH)NH₂, SO₂R, or COOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

15 n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages;

20 and, preferably, R₁ is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above);

25 R₂ is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms;

R₃ is the same as R₂; and


30 X is H, any halogen, OH, SH, OR', or SR', where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 4 carbon atoms.

These compounds are synthesized per the below synthesis scheme (as described in further detail in the Examples).

SCHEME 1

(PURINES)

Three basic synthesis protocols were utilized in Scheme I; to wit:


5 Method A

Generally, theobromine was used as the starting material under conditions to ensure N-1 alkylation took place in lieu of O-6 alkylation. Compounds 4 through 8, 10 and 11 (Table I) were prepared by this method.


5 Compounds 10 and 11 in particular were prepared by a variation of the alkylation method in which theobromine was first brominated to give 8-bromotheobromine (compound 9), then alkylated. The 8-bromo substituent was also displaced by NaSH to yield the corresponding 8-thioxo

10 derivatives, compounds 12 and 13.

Method B



This method is essentially based on the Traube purine synthesis protocol referred to *supra*. The method was used to prepare 1,3,8-trisubstituted xanthines bearing no alkyl group at the N-7 position. In this 5 procedure, the N-1 substituted pyrimidine was alkylated at position N-3. Formation of the purine ring was complete by nitrosation, reduction of the nitroso to the amine by catalytic hydrogenation, then ring closure using urea or potassium ethyl xanthate to provide compounds 24 10 and 25 (respectively, 8-oxo and 8-thioxo derivatives). A detailed description of this protocol is provided in the Examples.



(a) diethoxymethyl acetate
(b) CH₂I, NaOH
(c) R₁X, DMF, K₂CO₃


25 This method was utilized to prepare the N-3 propylpurines. The starting material used was n-propyl urea condensed with ethyl cyanoacetate in the presence of sodium ethoxide to yield the 6-amino-1-propylpyrimidinedione in moderate yield. Commercially 30 available 3-n-propylxanthine could also be used as the starting material.

Ring closure was accomplished as described in method A, except that diethoxymethyl acetate was used as the source of carbon in the ring closure step. Sequential alkylations were then performed using alkyl halides to 5 yield the final compound 31 (ethyl 4-(2,3,6,7-tetrahydro-2,6-dioxo-7-methyl-3-n-propyl-1H-purin-1-yl)butanoic acid). A detailed description of this protocol is provided in the Examples.

10 C. Pteridine synthesis.

The pteridines of the invention have the general formula (II):

15



R₁ is (CH₂)_nA, where:

20 A is NH₂, acyloxy, SO₃H, PO₄H₂, NNO(OH), SO₂NH₂, PO(OH)NH₂, SO₂R, or COOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

25 n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages;

30 and, preferably, R₁ is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8

carbon atoms, wherein the aromatic group further has as a substituent A (as defined above);

R₂ is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 5 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms;

R₄ is the same as R₂, OH or an O-alkyl having from 1 to 5 carbon atoms;

R₅ is the same as R₂, OH or an O-alkyl having from 1 to 5 carbon atoms; and,


Z is N or CH.

These compounds are synthesized per the below synthesis scheme (which is described in further detail in the Examples.)

SCHEME II

(PTERIDINES)

Method C (above) was chosen as a convenient method to produce N-alkyls in preference to O-alkyls in this group. Method C was modified to this end as follows:




Synthesis of the pteridines was based on orthodiaminopyrimidines as precursors. Ring closure of the orthodiamines (compounds 33 and 28) was accomplished with a two carbon source (e.g., glyoxal) to produce 5 compounds 34 and 35 (N-1 substituted pteridines). Alkylation at N-3 as described with respect to Method A produced the desired pteridines (compounds 36-38). Further, use of 3,4-hexanedione in the ring closure step 10 produced a more lipophilic derivative (compound 41; 6,7-diethyl pteridine). Condensation of compound 22 with dimethylacetylene dicarboxylate formed compound 39 (1,3-dialkylpteridine), while treatment of compound 27 phenethyl amine followed by alkylation provided compound 15 43 (6-phenyl dialkyl pteridine). Both of the latter protocols utilized a Timmis reaction to produce the desired products. A detailed description of these 20 protocols is provided in the Examples.

D. Thiadiazolopyrimidine synthesis.

20 The thiadiazolopyrimidines of the invention have the general formula (III):

25



R₁ is (CH₂)_nA, where:

20 A is NH₂, acyloxy, SO₃H, PO₄H₂, NNO(OH), SO₂NH₂, PO(OH)NH₂, SO₂R, or COOR where R is H, an alkyl having 30 from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or 5 amino linkages; and

and, preferably, R₁ is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above); and


10 R₂ is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms.

15 These compounds are synthesized per the below synthesis scheme (as described in further detail in the Examples).

SCHEME III

(THIADIAZOLOPYRIMIDINES)


Method C (above) was chosen as a convenient method to produce N-alkyls in preference to O-alkyls in this 5 group. Method C was modified to this end as follows:



15 Synthesis of the pyrimidines was based on orthodiaminopyrimidines as precursors. Ring closure of the orthodiamines was accomplished by treatment with thionyl chloride in the presence of pyridine. Alkylation of these intermediates produced compounds 47 and 48 20 (disubstituted pyrimidines). A detailed description of this protocol is provided in the Examples.

E. Isoquinolone Synthesis.

The isoquinolones of the inventions have the general 25 formula (IV):



(IV)

R_2 is $(CH_2)_nA$, where:

A is NH_2 , acyloxy, SO_3H , PO_4H_2 , $NNO(OH)$, SO_2NH_2 , $PO(OH)NH_2$, SO_2R , or $COOR$ where R is H, an alkyl having 5 from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in 10 place of a carbon atom to form, respectively, ether or amino linkages;

and, preferably, R_2 is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a 15 substituent A (as defined above); and

R_3 is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms;

20 R_4 is H, OH, NH_2 or O-alkyl having from 1-7 carbon atoms;

R_5 is H, OH, NO, NO_2 , NH_2 an O-alkyl having from 1-4 carbon atoms, or X where;

25 X is H, any halogen, OH, SH, OR', or SR', where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 4 carbon atoms; and,

R_7 is H, OH, NO, NO_2 , NH_2 an O-alkyl having from 1-7 carbon atoms, or X where:

30 X is H, any halogen, OH, SH, OR', or SR', where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 7 carbon atoms.

These compounds were synthesized by purchasing isoquinolines from Aldrich Chemical (see, FIGURE 14) and adding side chains to the ring structure as described above and in the Examples with respect to the purine, 5 pteridine and thiadiazolopyrimidine compounds of the invention. Only the 6,7-dimethoxy-1(2H)-isoquinoline compound (Aldrich # S52,626-6) had any inhibitory effect on TNF- α production prior to addition of the side chains described above (see also, Example 7).

10

F. Quinazoline Synthesis.

The quinazolines of the invention are synthesized according to the following scheme and are represented in structure by Compound 52:


15

Scheme IV

(DIDEAZAPTERIDINES OR QUINAZOLINES)

Compound 52 (a quinazoline derivative; ethyl 4-(1-methyl-2,4-dioxoquinazol-3-yl)butanoic acid) was produced as follows:

20



25

The starting material for this protocol was N-methyl isatoic anhydride. A detailed description of this protocol is provided in the examples.


G. Increasing the water solubility of Compounds.

The carboxylic ester and acid derivatives of the compounds described above can be converted to substituted carboxylic esters, where the substituent of the ester 5 increases the water solubility of the compounds. Particular substituents that increase the water solubility of the compounds effectively are aminoalkyl esters. The amino group of the aminoalkyl ester preferably is a secondary or tertiary amino group. The 10 amino substituents have between 1 and 6 carbon atoms, one of which can be replaced by an oxygen atom or nitrogen atom. The preferred aminoalkyl is a tertiary amine and the amino substituents are preferably are ether groups. The most preferred aminoalkyl is N-morpholinoethyl. The 15 carboxylic ester and carboxylic acid derivatives can be converted to the morpholinoethyl ester form by the method shown in Scheme V.

Scheme V

(MORPHOLINOETHYL DERIVATIVES)

Compound 53 (an isoquinolone derivative; ethyl (6,7-dimethoxy-1(2*H*)-isoquinolonyl)butanoic acid; prepared, 5 for example, according to Example 9) converted to compound 54, a morpholinoethyl ester (isolated as a hydrochloride salt) as follows:



II. Methods for Use of the Inventive Compounds.

The compounds of Formulas I through IV may be administered to a mammalian host to retard cellular responses associated with TNF- α and IL-1 production and 5 activation of the ceramide-mediated signal transduction pathway. In particular, the compounds of the invention may be administered to a mammal to retard activation of ceramide-dependent intracellular biochemical pathways in target cells without inhibiting the activity of 10 phosphodiesterase in the target cells or affecting the levels of diacylglycerol therein. As exemplified herein, the methods of the invention are expected to be of particular use in providing protection against inflammation and excessive formation of fibrotic tissue 15 by reducing the production of TNF- α by stimulated monocytes. As further exemplified herein, the compounds of the invention (particularly the isoquinolines and pteridines) are also expected to be efficacious in providing protection against cell senescence or cell 20 apoptosis, such as occurs as a result of trauma (e.g., radiation dermatitis) and aging (e.g., of the skin and other organs). In this context, the phrase "providing protection against" means clinically significant inhibition of cellular responses to stimuli (signals) 25 whose transmission to the cell is facilitated in whole or in part by the ceramide-mediated, sphingomyelin signal transduction pathway.

For purposes of this disclosure, therefore, 30 inflammation, fibroblast proliferation, cell senescence and cell apoptosis in response to ceramide-mediated signal transduction through the sphingomyelin pathway will be considered to be "ceramide associated" conditions. Those of ordinary skill in the art will be familiar with, or can readily ascertain, the identity and 35 clinical signs of specific ceramide associated conditions, and can identify clinical signs of

improvement therein (such as reductions in serum levels of TNF- α and improvement in clinical health) in addition to those exemplified herein.

For administration, the compounds of the invention 5 will preferably be formulated in a pharmaceutically acceptable carrier. Such carriers include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils 10 such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.

Parenteral vehicles include sodium chloride 15 solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other 20 additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.

Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium 25 stearate, stearic acid, microcrystalline cellulose, polymer hydrogels and the like. Similarly, the carrier or diluent may include any time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, microcapsules, 30 microspheres, liposomes, and hydrogels. For further reference, those of skill in the art may wish to consult the standard reference *Remington's Pharmaceutical Sciences* (which is incorporated herein by reference to illustrate knowledge in the art concerning suitable 35 pharmaceutical carriers).

A wide variety of pharmaceutical forms can be employed. Thus, when using a solid carrier the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a 5 troche, lozenge or suppository. When using a liquid carrier the preparation can be in the form of a liquid, such as an ampule, or as an aqueous or nonaqueous liquid suspension. Topical administration via timed release skin patches is also a suitable pharmaceutical form.

10 Dosages of the compounds of the invention will vary depending on the age, weight and presenting condition of the host to be treated, as well as the potency of the particular compound administered. Such variables will readily be accounted for by those of ordinary skill in 15 the clinical art. In particular, dosages will be adjusted upward or downward for each recipient based on the severity of the condition to be treated and accessibility of the target cells to the pharmaceutical formulations of the invention. Where possible, it will 20 be preferable to administer the pharmaceutical formulations of the invention locally at the site of the target cells; e.g., into inflamed skin or by infusion to another organ of the host. Thus, dosages will also vary depending on the route of administration and the extent 25 to which the formulations of the invention are expected to reach target cells before dilution or clearance of the formulation. Preferred routes of administration are by topical administration, local injection or parenteral infusion, although oral and intravascular routes may also 30 be utilized.

Generally, however, based on experience with other inhibitors of intracellular responses to external stimuli (such as pentoxyfylline) and the data provided herein, good results can be expected to be achieved in an adult 35 host of about 60 kg body weight in a dosage range of about 500 to about 4,000 mg/day, preferably between about

1,000 and about 3,500 mg/day (i.e., a "therapeutically effective dosage"). These dosages may be combined with other conventional pharmaceutical therapies for inflammation and fibrosis; e.g., administration of non-
5 steroid anti-inflammatory medications.

The compounds of the invention vary in potency. A summary of the potency of each compound (expressed as a percentage of inhibition of intracellular responses to LPS, namely, the production of TNF- α , where responses to
10 pure LPS=100% and are measured as the concentration of the inventive compound needed to inhibit TNF- α production by 50%) is provided in Table 1, above. Those of ordinary skill in the art will recognize that lesser or greater dosages of the compounds of the invention may be required
15 depending on the potency of the particular compound being administered.

III. Methods for Identification of Therapeutically Effective Analoques of the Compounds of the Invention.

Those of ordinary skill in the art will be familiar
20 with means to develop analogues to the compounds specifically described herein which, although not structurally identical thereto, possess the same biological activity. Such compounds are within the scope of the invention and may be identified according to the
25 protocols described below and in the Examples.

Though exposure of cells to the compounds of the invention under controlled conditions, the responsiveness of cells to inflammatory agents and intracellular mechanisms therefor can be investigated. This
30 information will not only better elucidate the intracellular pathways responsible for cellular responses to particular stimuli, but will also aid in the identification of anti-inflammatory and anti-fibrosis therapeutic compounds.

To identify and select therapeutic compounds for use in treating ceramide-associated conditions such as inflammation and fibrosis, cells (or intracellular components such as microsomes) which have not been exposed to an inflammatory or fibroblast proliferation inducing agent (e.g., LPS, TNF- α , IL-1, PDGF) are exposed to such an agent and the candidate therapeutic compound. Specifically, a control group of cells is incubated with a known amount of the inflammatory or fibroblast proliferation inducing agent. Treatment groups of cells are exposed to the same amount of inflammatory or fibroblast proliferation inducing agent as well as aliquots of the candidate therapeutic compound. Inflammatory responses or fibroblast proliferation in each group are detected by conventional means known to those of skill in the art (such as the assay steps described in the examples) and compared.

To identify and select therapeutic compounds for use in treating ceramide-associated conditions of cell senescence and apoptosis, cells (or intracellular components such as microsomes) which have not been exposed to a senescence or apoptosis inducing agent (e.g., cytokines such as TNF- α and exogenous stimuli such as heat, radiation and chemical agents), are exposed to such an agent and to the candidate therapeutic compound. Inhibition of senescence or apoptosis is measured as a function of cell growth. Those of ordinary skill in the art will be familiar with techniques for obtaining such measurements, examples of which are provided below.

"Therapeutically effective compounds" will be those which, when administered according to the invention and sound medical practices, provide cells with protection against ceramide-associated conditions compared to control values for cellular reactions to a ceramide-associated condition inducing agent.

The invention having been fully described, examples illustrating its practice are set forth below. These examples should not, however, be considered to limit the scope of the invention, which is defined by the appended 5 claims.

In the examples, the abbreviation "min." refers to minutes, "hrs" and "h" refer to hours, and measurement units (such as "ml") are referred to by standard abbreviations. "mp" refers to melting point.

EXAMPLE 1

INHIBITION OF CELL SENESCENCE AFTER SERUM DEPRIVATION
IN SERUM-DEPENDENT CELLS

Many cell types are dependent upon serum factors for
5 growth. Thus, deprivation of such cells of serum
provides a model for assessment of compounds to modulate
cell responses to intracellular ceramide-mediated signal
transduction. In particular, withdrawal of serum from
serum-dependent cell cultures produces increased
10 intracellular levels of endogenous ceramide and may also
increase intracellular levels of endogenous diacyl
glycerol (see, e.g., Jayadev, et al., *J.Biol.Chem.*,
270:2047-2052, 1995).

To evaluate the inhibitory effect of the compounds
15 of the invention on ceramide-associated conditions *in*
vitro, the serum withdrawal model was used.
Specifically, 3T3 fibroblast cells were seeded in 96 well
microtiter plates in DMEM in the presence of 10% fetal
bovine serum. The cells were incubated to 90%
20 confluence.

The medium was removed, the cells washed and
reincubated in serum-free DMEM. Compound no. 37 and cell
permeable ceramide were added to the wells at
concentrations of, respectively, 0, 4, 40 or 400 μ M
25 compound no. 37 and 0, 5 or 10 μ M of ceramide. After 24
hrs. incubation, 0.5 μ Ci of [3 H] thymidine was added to
each well for 2 hrs. DNA synthesis in the tested cell
population was assessed by conventional techniques for
30 detection of [3 H] thymidine incorporation. The results of
this assay are indicated in FIGURE 1 and establish the
cell senescence inhibitory efficacy of the inventive
compounds (as represented by compound no. 37).

EXAMPLE 2

INHIBITION OF CELL APOPTOSIS AFTER CD95 STIMULATION

Engagement of cell surface receptor CD95 (also known 5 as Fas/Apo-1 antigen) triggers cell apoptosis. DX2 is a functional anti-FAS (CD95) antibody which will, on binding of CD95, activate the Smase catalysis of sphingomyelin hydrolysis and production of ceramide (see, re DX2, Cifone, et al., *J.Exp.Med.*, 177:1547-1552, 1993, 10 the disclosure of which is incorporated herein by reference for use in accessing the DX2 antibody). Thus, binding of CD95 is a model for induction of apoptosis via the sphingomyelin signal transduction pathway.

To assess the inhibitory effect of the compounds of 15 the invention on ceramide-mediated cell apoptosis, human T lymphoblasts (Jurkat) were suspended at 2×10^6 cells per ml in RPMI-1640 supplemented with insulin, transferrin, selenium and glutamine. After incubation for 2 hrs. at room temperature with either compound no. 37, compound 20 no. 6, pentoxyfylline or a control compound (Ro-1724), 25 ng/ml of anti-FAS antibody was added to each suspension. After another 2 hrs., cell apoptosis was measured as a function of the number of cells (counted by hemocytometer) that excluded the vital dye erythrosin B. 25 The results of the experiment are indicated in FIGURE 2 and establish the apoptosis inhibitory efficacy of the compounds of the invention (as represented by compounds nos. 6 and 37, particularly the latter).

To assess the inhibitory effect of the compounds of 30 the invention on death of human lymphocytes, human peripheral blood lymphocytes were isolated from normal human blood and depleted of monocytes by adherence to a plastic substrate. Lymphocytes were then cultured in RPMI-1640 medium with 10% autologous plasma at an initial 35 concentration of 2×10^6 cells per ml. Aliquots of the cell

samples were divided and one half of the samples were incubated with either compound 37 or compound 1L-49 (an isoquinolone, the structure of which is shown in Example 7) for four days. The remaining half of the samples were 5 allowed to rest for four days. Cell viability after four days was determined by erythrosin B dye exclusion in a hemocytometer.

As shown in FIGURE 13, at increasing concentrations, the compounds of the invention (as represented by 10 compounds 37 and 1L-49) protected the cell sample population from death by up to 100% as compared to the survival rate of untreated lymphocytes.

EXAMPLE 3

15 INHIBITION OF THE ACTIVITY OF CERAMIDE ACTIVATED PROTEIN

KINASE

Ceramide-activated protein kinase (CaPK) is a 97 kDa protein which is exclusively membrane-bound and is believed to serve a role in the sphingomyelin signal 20 transduction pathway. In particular, CaPK is believed to mediate phosphorylation of a peptide derived from the amino acid sequence surrounding Thr⁶⁶⁹ of the epidermal growth factor receptor (i.e., amino acids 663-681). This site is also recognized by the mitogen-activated kinase. 25 MAP (also known as a family of extracellular signal-regulated kinases). Thus, the effect of the compounds of the invention on CaPK activity in cells is indicative of the effect that the compounds exert on signal transduction in the sphingomyelin pathway.

30 To that end, Jurkat cells were suspended at 2x10⁶ cells per ml in RPMI-1640 medium as described in Example 2. After incubation for 2 hrs., either compound 37, 20 μ M of ceramide or 25 ng/ml of anti-FAS antibody DX2 were added to each suspension and incubated for 15 mins.

After centrifugation and washing, the cells were separately homogenized in a dounce homogenizer.

Ceramide kinase levels in each test sample were assayed as described by Liu, et al., *J.Biol.Chem.*, 5 269:3047-3052, 1994 (the disclosure of which is incorporated herein for reference and use in assaying ceramide kinase). Briefly, the membrane fraction was isolated from each test sample of treated cell homogenate by ultracentrifugation and run on a 10% PAGE gel. The 10 gel was washed with guanidine-HCL, and renatured in HEPES buffer. Then [³²P]-ATP was added to the gel and left there for 10 mins. Thereafter, the gel was extensively washed with 5% TCA. Autophosphorylated kinase was detected by autoradiography. The results of this assay 15 are indicated in FIGURE 3, and establish the CaPK inhibitory efficacy of the compounds of the invention (as represented by compound 37).

EXAMPLE 4

20 ABSORBANCE OF UVB RADIATION BY THE COMPOUNDS OF THE
INVENTION

Radiation (particularly in the UVB wavelength) is a major cause of skin damage (including apoptosis) in humans. As indicated elsewhere above, the sphingomyelin 25 signal transduction pathway is believed to be involved in at least the early stages of development of radiation induced dermatoses (including radiation dermatitis, sunburn and UVB induced immune suppression from radiation damage to Langerhans cells in the skin- see, e.g., Haimovitz-Friedman, et al., *J.Exp.Med.*, 180:525-535, 1994 (cellular responses to ionizing radiation); and, Kurimoto and Streilein, *J.Immunol.*, 145:3072-3078, 1992 (cutnaceous immune suppression from UVB exposure)). Thus, a compound which will inhibit cell responses to 30 stimulus of the sphingomyelin signal transduction pathway

by radiation and can be administered topically at the site of exposure would be of great benefit in retarding the damage associated with radiation exposure (e.g., through exposure to sunlight or radiation).

5 To assess the radiation absorbing abilities of the compounds of the invention, the ultraviolet spectra of compounds of the invention (nos. 6 and 37, alone, in combination and as 8-oxo derivatives) were evaluated and compared to those of a commercially available sunscreen
10 additive (PABA) and isoquinoline. The spectra were identified using a KONTRON analytical instrument. As indicated in FIGURE 4, the compounds of the invention (as represented by compounds nos. 6 and 37) absorbed through most of the UVB region, indicating efficacy in absorbing
15 radiation. Surprisingly, a mixture of compound nos. 6 and 37 proved to absorb throughout the UVB region. Thus, given the somewhat greater absorbance characteristics of compound 37 vis-a-vis compound 6, it can be reasonably expected that mixtures of the two in ratios of 1:1 or
20 greater (favoring compound 37) will have substantial synergistic efficacy in absorbing radiation and retarding its effects on cells.

EXAMPLE 5

INHIBITION OF TNF- α PRODUCTION BY THE COMPOUNDS OF THE INVENTION

As shown in FIGURE 5(a), compounds of the invention having N-1 chain lengths from 2-5 carbons are especially useful in inhibiting TNF- α production *in vitro*, while N-1 chain lengths of about 4 carbons (with a terminal ester) appear to be optimal in this respect (as compared to a control compound; FIGURE 5(b)). Further, the esterified compounds were significantly more effective inhibitors of TNF- α production than their carboxylic counterparts. These data were obtained as follows:

Peripheral blood mononuclear cells were isolated from normal human blood on Hypaque-Ficoll density gradients. A portion of the isolated cells were further purified by adherence to gelatin coated flasks.

100 μ l aliquots of monocytes were placed onto 96 well microtiter plates at a density of 5×10^5 cells/ml in RPMI-1640 medium containing 10% fetal bovine serum. After incubation for 24 hrs., various concentrations of the test compounds (FIGURE 5) were added to the plated cells in a volume of 100 μ l and incubated for 1 hr. After incubation, 1 μ g/ml of LPS was added to each well.

18 hrs. after exposure of the plated cells to LPS, 100 μ l of medium was collected from each well and assayed (by ELISA) for release of TNF- α , using recombinant human TNF as a standard. The sensitivity of the assay ranged from 10-100 pg/ml.

EXAMPLE 6

RELATIVELY LOW INHIBITION OF PHOSPHODIESTERASE IVACTIVITY BY COMPOUNDS OF THE INVENTION

As shown in FIGURE 6, there appears to be little
5 correlation between the efficacy of the compounds of the
invention in inhibiting the activity of phosphodiesterase
and inhibiting activity of TNF- α . For example, the most
active pteridine compound in inhibiting TNF- α production
in vitro (#37) was a very poor inhibitor of
10 phosphodiesterase IV, even at micromolar concentrations.

These data confirm that the compounds of the
invention do not target phosphodiesterase to control TNF-
 α production. The data were obtained as follows:

The reaction was started with the addition of PDE
15 and incubated at 37°C for 10 minutes, then terminated by
boiling for 2 minutes. 500 μ l of 0.1 M HEPES/0.1 M NaCl
(pH 8.5) was added to each tube, then the reaction
mixture was applied to a boronate column. Unreacted CaMP
was washed off with Hepes/NaCl and the reaction mixture
20 eluted with acetic acid. Recovery was determined with
the [14 C]-AMP.

EXAMPLE 7

IN VIVO AND IN VITRO LEUKOPENIA IN RESPONSE TO LPS AND
25 INHIBITION OF SAME BY THE COMPOUNDS OF THE INVENTION

As shown in FIGURES 7 through 9 and Table 1, the
compounds of the invention effectively reduce cellular
response to LPS, a known inducer of TNF- α production. In
the presence of ceramide, the inhibitory activity of the
30 compounds of the invention on LPS induced leukopenia (a
phenomenon dependent on TNF- α induced surface expression
of the P-selection class of adhesion molecules) was
enhanced (FIGURE 7). However, the inhibitory activity of

the compounds of the invention was essentially unaffected by diacylglycerol (FIGURE 8), indicating that the mode of action of the compounds of the invention are not dependent on hydrolysis of phosphatidic acid. These data 5 were obtained as follows:

The leukopenia inhibitory capacity of the test compounds was determined by intraperitoneal administration of 0.5 μ g of LPS in saline to ICR female mice (age 6-8 weeks; weight 19-23 g). One hour before 10 receiving the LPS, the mice received the test compound by intraperitoneal injection at a dose of 50 mg/kg (in isotonic saline). Two hours after injection of LPS, 200 μ l of blood was collected from each mouse into a heparinized tube and the total count of nucleated cells 15 determined in a hemocytometer (FIGURE 7 and 9).

Calcium independent protein kinase activity was measured, using a 1% triton X-100 extract of Jurkat cells (5×10^8 /ml). The reaction mixture consisted of 20 mM Tris HCl pH 7.5, 20 mM MgCl₂, 20 μ M ATP containing 200,000 cpm 20 [γ 32P] ATP, and 50 μ M Myelin Basic Protein. The extract was pre-incubated with A) compound 37 B) compound 37 with or without 10 μ M ceramide C) ceramide or D) dihydro ceramide for 15 minutes, followed by addition of substrate and ATP, and incubation at 30°C for 5 minutes. 25 The total count of nucleated cells was measured in a hemocytometer (FIGURE 9). The same protocol was followed to obtain the results shown in FIGURE 8 (with the addition of diacyl glycerol to some of the test mixtures). 30 An isoquinoline compound of the invention was also tested *in vitro* for its inhibitory efficacy with respect to LPS induced TNF- α production in human cells. The structure of the compound, 1I-49, is described below:

Human macrophages were cultured in 96 well 35 microtiter plates and incubated with LPS. Aliquots of

the stimulated cells were then incubated with, respectively, 0.1, 1, 10, 100 or 1000 μ M of 1I-49, compound 37 and a commercially available isoquinoline (6,7-dimethoxy-1(2H)-isoquinoline from Aldrich Chemical; 5 labelled S52-626-6 in FIGURE 10) which, like the compounds of the invention, has an oxygen ortho to a ring nitrogen but, unlike the compounds of the invention, lacks a side chain substituent as described above (1L-49 is representative of the isoquinolone compounds of the 10 invention having the side chain substituents described elsewhere above). The inhibitory efficacy of each compound was measured as a function of TNF- α reduction in pg/ml. The results of the experiment are indicated in FIGURE 10 and establish that the compounds of the 15 invention (represented by 1I-49 and compound 37) have inhibitory efficacy with respect to reduction in LPS induced TNF- α production by human cells. Other isoquinolines tested (FIGURE 14) did not exert inhibitory activity in the absence of the side chain substituents 20 added according to the invention.

EXAMPLE 8

FIBROBLAST PROLIFERATION IN RESPONSE TO LPS AND INHIBITION OF SAME BY THE COMPOUNDS OF THE INVENTION

25 As shown in FIGURE 11, PDGF induced fibroblast proliferation was selectively inhibited by the compounds of the invention. In addition, the compounds were shown not to be cytostatic or cytotoxic, insofar as they did not alter EGF-triggered mitogenesis in the cells tested 30 (FIGURE 12).

These data were obtained as follows:

Mouse fibroblast line 3T3 cells (American Type Culture Collection #CCL 92) were seeded into 96 well plates in complete medium and allowed to grow to

confluence. The medium was then replaced with medium-free serum and the cells incubated for 24 hrs.

The test compounds were then incubated with the cells for 1 hr before addition of 5 ng/ml human PDGF or 5 EGF was added to each well. After another 24 hrs, 1 μ Ci of [3 H]-thymidine was added to each well. 4 hrs later the cells were harvested onto glass fiber filters and the cellular incorporation of [3 H]-thymidine was measured by liquid scintillation counting (FIGURES 11 and 12).

10

EXAMPLE 9

SYNTHESIS OF COMPOUNDS 2, 4-8 AND 10-13

General Alkylation Procedure for Compounds 4-8, 10, 11 (Method A):

15 Theobromine or 8-bromotheobromine (2 mmol) was combined with anhydrous K_2CO_3 (2.5 mmol) and dry DMF (15 mL) and the mixture was brought to 75°C. The appropriate alkyl halide (2.5 mmol) was added and the mixture was stirred at 75°C for 2-18 h. The reaction mixture was 20 cooled, poured into water (125 mL) and extracted with ethyl acetate (2 x 75 mL). The organic layer was dried over magnesium sulfate and evaporated to yield a colorless oil or white solid which was triturated with ethyl ether. The resulting solid, often analytically 25 pure, may be purified further if desired by crystallization from a small amount of ethanol. Yields 58-89%. Compounds 15-17, 31, 36-38, 41, 43, 47, and 48 (described below) were prepared by this same procedure only using the appropriate precursors in place of 30 theobromine.

General Thiation Procedure for Compounds 12 and 13:

The 8-bromoxanthine 10 or 11 (0.25 mmol) was suspended in anhydrous ethanol (10 mL) and heated to reflux. $NaSH \cdot (H_2O)_x$ (2.5 mmol) was added and the mixture

became clear, green almost immediately. The mixture was stirred under reflux for 30 min, cooled and evaporated onto silica gel. Flash column chromatography using 5-7% MeOH in CH_2Cl_2 provided a 63% and 75% yield of 12 and 13, 5 respectively as white solids. Note: Compound 13 was found by ^1H NMR to be the ethyl ester due to transesterification under the reaction conditions.

^1H NMR spectra and elemental analyses or exact mass data were consistent with the assigned structures (see, 10 Table 2 following Example 9).

EXAMPLE 10

SYNTHESIS OF COMPOUNDS 24, 25, 31 AND INTERMEDIATES

General Procedure for C-Nitrosation of Pyrimidines
15 (Compounds 18-20, 27, and 32):

The pyrimidine (15 mmol) was suspended in N HCl (30 mL) and an aqueous solution of sodium nitrite (20 mmol in 10 mL) was dripped in with stirring over 10 min. The suspension went from off-white to purple almost 20 immediately. Stirring was continued for 1h, pH adjusted to 5 with ammonia water and the purple solid product collected to provide 75-90% yield after drying. The characteristic lack of the C-5 proton in the ^1H NMR was evident for each compound (Table 2).

25 General Procedure for the Reduction of 5-Nitroso to 5-Amino Pyrimidines (Compounds 21-23, 28, and 33):

The 5-nitrosopyrimidine (15 mmol) was suspended in water (50 mL) and heated to 80-90°C. With stirring, sodium hydrosulfite (45 mmol) was added in portions over 30 5 min. The color quickly changed from purple to light green and stirring was continued an additional 10 min. The mixture was cooled in ice and filtered. The filtered solid was washed with cold water, EtOH and Et_2O to provide

the orthodiamine in 70-88% yield as a tan to pale green solid.

Synthesis of 1-n-Hexyl-3-methyluric acid intermediate (24):

5 The nitrosopyrimidine 19 (270 mg, 1.06 mmol) was dissolved in ethanol (20 mL) with warming and palladium on carbon (75 mg, 10%) was added under argon. Hydrogenation was performed at room temperature and 15 psi for 2 h, filtered to remove catalyst and evaporated 10 to dryness. The residue was combined with urea (600 mg, 10 mmol) and heated neat on the hot plate with stirring. The temperature reached 140°C which produced a clear melt and was maintained for about 10 min. with additional urea added (1 g). Upon cooling the melt solidified and was 15 dissolved in n NaOH (25 mL) and boiled with decolorizing carbon for 10 min., filtered and acidified to pH 3-4 while hot. The resulting precipitate was collected after cooling and washed with water and dried to yield 160 mg (57%) of 24 as an off-white solid with the following 20 characteristics: mp >290°C dec. ¹H NMR (500 MHZ, DMSO-d₆) δ 11.80 and 10.73 (2s, 2H, N-7 H, N-9 H), 3.78 (t, 2H, N-CH₂), 3.30 (s, 3H, N-CH₃, under H₂O signal), 1.48 (m, 2H, 2'CH₂), 1.24 (m, 6H, 3', 4', 5' CH₂), 0.85 (t, 3H, CH₃). Analysis: C₁₂H₁₈N₄O₃ (C, H, N; Table 2).

25 Synthesis of 3-Methyl-8-thiouric acid (25) intermediate:

The pyrimidinediamine 33 (100 mg, 0.63 mmol) was combined with potassium ethyl xanthate (810 mg, 5 mmol) and DMF (10 mL) and heated at 100°C. The suspension 30 became green almost immediately and reaction was complete after 30 min. by TLC. After a total reaction time of 1 h, the mixture was cooled, filtered and washed with Et₂O, dried to yield an off-white solid (310 mg) which presumably contained the unreacted potassium ethyl xanthate and the potassium salt of the desired product.

The solid was suspended in water (5 mL) and heated to dissolve. Glacial acetic acid was added to pH 5 and a vigorous effervescence was noted. A white solid formed which was filtered warm and washed with water, then 5 ethanol and dried to yield 99 mg (79%) of the title compound. ^1H NMR (DMSO-d₆) δ 13.40, 12.92 and 11.80 (3br s, 3H, NHs), 3.28 (s, 3H, CH₃). Analysis: C₆H₆N₄O₂S (C, H, N; Table 2).

Synthesis of 3-n-Propylxanthine (29) intermediate:

10 The pyrimidinediamine 28 (750 mg) was combined with diethoxymethyl acetate (7 mL) and heated at 80°C for 2 h. The mixture was evaporated to dryness and water (5 mL) was added and the mixture heated for 20 min. to near boiling. The resulting solution was then allowed to 15 evaporate slowly to yield off-white crystals. Yield 680 mg (86%); mp 282-284°C, Lit.¹⁵ 291-292°C.

EXAMPLE 11

SYNTHESIS OF COMPOUNDS 36-39, 41 AND 43 AND INTERMEDIATES

20 General Procedure for Ring Closure of Pyrimidine-diamines to Pteridines:

The orthodiamine 28 or 33 (2 mmol) was suspended in water (20 mL) and heated to above 70°C before a solution of glyoxal-sodium bisulfite addition product (10 mmol in 25 25 mL water) was added with stirring. The pale green suspension slowly became light amber and clear. After heating 5 min TLC indicated reaction was complete. The mixture was cooled and extracted with ethyl acetate (5 x 40 mL), dried over MgSO₄ and evaporated to yield the 1-methyl (34) or 1-n-propylpteridine (35) in 71 and 78 %, respectively. ^1H NMR showed the appearance of two 30 aromatic signals at about 8.74 and 8.55 as doublets (J = 2.5 Hz) for both compounds.

Synthesis of 6,7-Diethyl-1-methylpteridine-2,4-dione
(40) intermediate:

Compound 33 (200 mg, 1.27 mmol) was suspended in acetonitrile (5 mL) and 3,4-hexanedione (185 μ L, 1.52 mmol) was added. The mixture was heated at 70°C for 15 min with minimal product formation due to insolubility of 33. Therefore DMF (3 mL) and water (3 mL) were added and the temperature was raised to 100°C. After 90 min total reaction time the mixture was cooled and poured into water (100 mL) and extracted with ethyl acetate (3 x 75 mL). The organic layer was dried over MgSO_4 and evaporated to provide the colorless crystalline product. Yield 240 mg (81%); mp 218-222°C; ^1H NMR (DMSO- d_6) δ 11.78 (br s, 1H, NH), 3.46 (s, 3H, NCH_3), 2.95 and 2.93 (2q, 4H, 15 2CH_2 of ethyls), 1.28 and 1.23 (2t, 6H, 2CH_3 of ethyls). Analysis: $\text{C}_{11}\text{H}_{14}\text{N}_4\text{O}_2$ (C, H, N; Table 2).

Synthesis of 1-Methyl-6-phenylpteridine-2,4-dione
(42) intermediate:

The nitrosopyrimidine 32 (220 mg, 1.28 mmol) was mixed thoroughly with phenethyl amine hydrochloride (1.5 g, 9.5 mmol) and heated in an open beaker on the hot plate. After a few minutes at about 160°C the purple reaction mixture fused to a brown paste. TLC indicated many products so sulfolane (1 mL) was added and heat was continued for 15 min. The reaction mixture was heated in water (10 mL) and then diluted 50 mL in water and extracted with ethyl acetate (2 x 50 mL), the organic layer dried over MgSO_4 and then concentrated. The residue was flash chromatographed on silica gel using 4% MeOH in CH_2Cl_2 . Yield 75 mg (23%) of 42 as a pale yellow-orange solid. mp >307°C dec.; ^1H NMR (500 MHZ, DMSO- d_6) δ 11.95 (br s, 1H, NH), 9.37 (s, 1H, C-7 H), 8.17 (m, 2H, 2',6' phenyl), 7.55 (m, 3H, 3',4',5' phenyl), 3.51 (s, 3H, NCH_3). Anal. $\text{C}_{13}\text{H}_{10}\text{N}_4\text{O}_2$ (C, H, N).

EXAMPLE 12

SYNTHESIS OF COMPOUNDS 44, 47 AND 48

General Method for Ring Closure of Pyrimidines to Thiadiazolo-pyrimidines (Compounds 44-46):

5 The orthodiamine 23, 27, or 32 (2.3 mmol) was suspended in dry acetonitrile (5 mL) and dry pyridine (1.5 mL) was added. Thionyl chloride (1 mL, 13.7 mmol) was added quickly and the mixture, which became clear and darkened, was heated at 60°C for 10 min. The mixture was
10 then cooled and poured into n HCl (40 mL) with stirring. The resulting yellow solution was extracted with ethyl acetate (3 x 40 mL), dried over MgSO₄ and evaporated to yield a pale yellow solid which was triturated with ether. Yield 65-74%.

15

Alkylation of these intermediates yielded the disubstituted products 47 and 48.

EXAMPLE 13

20

SYNTHESIS OF COMPOUNDS 50 AND 52Ethyl 4-[(2-methylamino)benzoyl]aminobutanoate (51):

A mixture of N-methylisatoic anhydride (3.5 g, 19.8 mmol) was combined with 4-aminobutyric acid (2.5 g, 24.3 mmol) in dry DMF (50 mL) and heated at 100°C for 2 h.
25 TLC indicated reaction to be complete and the DMF was removed in vacuo. The residue was used directly for esterification which was accomplished by dissolving the residue in 100% ethanol (50 mL) and adding chlorotrimethyl silane (2.5 mL, 20 mmol). The mixture
30 was heated at 65°C for 6 h and then evaporated to yield a brown syrup. Crude yield 87% from isatoic anhydride. A small sample was purified for characterization and biological testing by preparative TLC using 7% MeOH in

CH_2Cl_2 . The remainder of the material was used directly for preparation of compound 52. Analysis: $\text{C}_{14}\text{H}_{20}\text{N}_2\text{O}_3$ (C, H, N; Table 2).

Ethyl 1-Methyl-1,4-dihydro-2,4-dioxo-3(2H)-5 quinazolinebutanoate (52):

The residue from 51 was combined with ethyl chloroformate (10 mL) and heated at 90°C for 1 h. The mixture was cooled and poured into saturated aqueous sodium bicarbonate (50 mL) with stirring and after 10 min extracted with ethyl acetate (2 x 75 mL). The organic layer was dried over MgSO_4 and evaporated to yield a brown syrup. The crude product was flash chromatographed on silica using 3% MeOH in CH_2Cl_2 to yield g (%) of 52 as a thick oil. ^1H NMR (500 MHZ, DMSO- d_6) δ 7.27-7.42 (2m, 4H, C-5,6,7,8), 4.04 (t, 2H, CH_2 of ethyl), 3.88 (m, 2H, NCH_2), 3.11 (s, 3H, NCH_3), 2.33 (t, 2H, 2' CH_2), 1.71 (m, 2H, 3' CH_2). Analysis: $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_4$ (C, H, N; Table 2).

TABLE 2ANALYSIS OF SELECTED INVENTIVE COMPOUNDS AND
INTERMEDIATES (Combustion Elemental Analysis)

5 4 Calc'd for

C₁₁H₁₄N₄O₄: C, 49.62; H, 5.30; N, 21.04.

Found: C, 49.54; H, 5.31; N, 21.12.

5 Calc'd for

10 C₁₂H₁₆N₄O₄ + H⁺: HRMS 281.124980

Found: 281.123300

6 Calc'd for

C₁₃H₁₈N₄O₄: C, 53.05; H, 6.16; N, 19.04.

15 Found: C, 52.79; H, 6.00; N, 18.99.

7 Calc'd for

C₁₄H₂₀N₄O₄: C, 54.54; H, 6.54; N, 18.17.

Found: C, 54.47; H, 6.42; N, 18.16.

20

8 Calc'd for

C₁₆H₁₆N₄O₄.2/3 DMF: C, 57.29; H, 5.52; N, 17.33.

Found: C, 57.17; H, 5.51; N, 17.35.

10 Calc'd for

$C_{13}H_{17}BrN_4O_4$: C, 41.84; H, 4.59; N, 15.01.

Found: C, 41.83; H, 4.43; N, 14.99.

5

11 Calc'd for

$C_{16}H_{15}BrN_4O_4$: C, 47.19; H, 3.71; N, 13.76.

Found: C, 47.02; H, 3.68; N, 13.63.

10 12 Calc'd for

$C_{13}H_{18}N_4O_4S$: C, 47.84; H, 5.56; N, 17.17.

Found: C, 47.98; H, 5.44; N, 16.99.

13 Calc'd for

15 $C_{17}H_{18}N_4O_4S$: C, 54.53; H, 4.85; N, 14.96.

Found: C, 54.41; H, 4.66; N, 14.72.

20 Calc'd for

$C_{12}H_{20}N_4O_3$: C, 53.72; H, 7.51; N, 20.88.

20 Found: C, 54.00; H, 7.47; N, 20.65.

4 Calc'd for

$C_{12}H_{18}N_4O_3$: C, 54.12; H, 6.81; N, 21.04.

Found: C, 54.23; H, 6.76; N, 21.04.

25

31 Calc'd for

$C_{15}H_{22}N_4O_4$: C, 55.89; H, 6.88; N, 17.38.

Found: C, 55.67; H, 6.94; N, 17.22.

5

33 Calc'd for

$C_5H_8N_4O_4$: C, 38.46; H, 5.16; N, 35.88.

Found: C, 38.22; H, 5.13; N, 35.84.

10 34 Calc'd for

$C_7H_6N_4O_2$: C, 47.19; H, 3.39; N, 31.45.

Found: C, 47.01; H, 3.18; N, 31.25.

35 Calc'd for

15 $C_9H_{10}N_4O_2$: C, 52.42; H, 4.89; N, 27.17.

Found: C, 52.20; H, 4.74; N, 27.22.

36 Calc'd for

$C_{13}H_{16}N_4O_4$: C, 53.42; H, 5.52; N, 19.17.

20 Found: C, 53.39; H, 5.43; N, 19.17.

36a Calc'd for

$C_{11}H_{12}N_4O_4$: C, 50.00; H, 4.58; N, 21.20.

Found: C, 49.92; H, 4.47; N, 21.26.

25

37 Calc'd for

$C_{15}H_{20}N_4O_4$: C, 56.24; H, 6.29; N, 17.49.

Found: C, 56.04; H, 6.12; N, 17.42.

5

37a Calc'd for

$C_{13}H_{16}N_4O_4 \cdot 4/5H_2O$: C, 50.91; H, 5.78; N, 18.27.

Found: C, 50.64; H, 5.81; N, 18.23.

10 38 Calc'd for

$C_{12}H_{18}N_4O_4 + H^+$: HRMS 277.093680

Found: 277.093800

39 Calc'd for

15 $C_{17}H_{22}N_4O_6$: C, 53.96; H, 5.86; N, 14.81.

Found: C, 53.60; H, 5.73; N, 14.04.

40 Calc'd for

$C_{11}H_{14}N_4O_4 \cdot 1/4H_2O$: C, 55.34; H, 6.12; N, 23.47.

20 Found: C, 55.37; H, 6.02; N, 23.43.

41 Calc'd for

$C_{17}H_{24}N_4O_4$: C, 58.61; H, 6.94; N, 16.08.

Found: C, 59.22; H, 7.08; N, 15.69.

25

41a Calc'd for

$C_{15}H_{20}N_4O_4$: C, 56.24; H, 6.29; N, 17.49.

Found: C, 56.41; H, 6.27; N, 17.28.

5

42 Calc'd for

$C_{13}H_{10}N_4O_4 \cdot 1/3H_2O$: C, 60.00; H, 4.13; N, 21.53.

Found: C, 59.78; H, 3.70; N, 21.14.

10 43 Calc'd for

$C_{19}H_{20}N_4O_4 + H^+$: HRMS 369.156280

Found: 369.154800

44 Calc'd for

15 $C_{12}H_{18}N_4O_2S + H^+$: HRMS 283.122873

Found: 283.121300

45 Calc'd for

$C_5H_4N_4O_2S$: C, 32.61; H, 2.19; N, 30.42.

20 Found: C, 32.65; H, 2.20; N, 30.29.

46 Calc'd for

$C_7H_8N_4O_2S$: C, 39.62; H, 3.80; N, 26.40.

Found: C, 39.84; H, 3.60; N, 26.02.

25

47 Calc'd for

$C_{11}H_{14}N_4O_4S$: C, 44.29; H, 4.73; N, 18.78.

Found: C, 44.57; H, 4.67; N, 18.80.

5

47a Calc'd for

$C_9H_{10}N_4O_4S + H^+$: HRMS 271.050102

Found: 271.050600

10 48 Calc'd for

$C_{13}H_{18}N_4O_4$: C, 47.84; H, 5.56; N, 17.17.

Found: C, 47.97; H, 5.66; N, 17.08.

51 Calc'd for

15 $C_{14}H_{20}N_2O_3 \cdot 1/2H_2O$: C, 61.52; H, 7.74; N, 10.25.

Found: C, 61.54; H, 7.44; N, 9.77.

52 Calc'd for

20 $C_{15}H_{18}N_2O_4CH_3OH$: C, 59.62; H, 6.88; N, 8.69.

Found: C, 60.61; H, 6.84; N, 8.58.

52a Calc'd for

25 $C_{13}H_{14}N_2O_4$: C, 59.54; H, 5.38; N, 10.68.

Found: C, 59.55; H, 5.32; N, 10.59.

25

EXAMPLE 14

SYNTHESIS OF HIGHLY WATER SOLUBLE DERIVATIVES

5 Acid Hydrolysis of Compound 53.

Compound 53 (1.63 g, 5.1 mmol) (prepared according to Example 9 from the parent isoquinolone) was combined with n HCl (30 mL) and was heated at boiling for 75 min. The mixture was cooled and the resulting solid which 10 formed was filtered, washed with cold water, and dried to yield 1.5 g (quantitative conversion) of the free carboxylic acid of suitable purity for esterification (as judged by TLC).

Esterification to form morpholinoethyl ester Compound 54.

15 The carboxylic acid obtained above in this Example (1.0 g, 3.4 mmol) was dissolved in dichloromethane (25 mL) with warming and then thionyl chloride (1 mL, 13.7 mmol) was added followed by 3 drops of DMF. After a few minutes a white solid precipitated (acid chloride 20 intermediate), but the reaction mixture was allowed to stir at room temperature overnight. The mixture was evaporated to remove excess thionyl chloride and the residue was suspended in dry acetonitrile (25 mL). To this mixture was added morpholinoethanol (1.24 mL, 10.2 mmol) and heated at 80°C for 5 minutes. The solid 25 suspension became clear almost immediately and after cooling, the reaction mixture was evaporated onto silica gel and loaded on a flash silica gel column and eluted with methanol - dichloromethane 5/95. The fractions of 30 pure product were pooled and evaporated to yield an off-white residue which was dissolved in isopropyl alcohol (5 mL) and concentrated HCl (1 mL) was added. Upon concentration in vacuo, an off-white solid formed. Yield after drying 0.93 g (62%), mp 90°C. Proton NMR confirms 35 structure assignment as the morpholino ethyl ester of

Compound 53: ^1H NMR (DMSO-d₆, 500 MHZ) δ 7.56 and 7.15 (2s, 2H, C-5 and C-8 aromatics), 7.35 and 6.55 (2d, 2H, C-3 and C-4 aromatics), 4.37 (m, 2H, C-1' of ester), 3.92 (m, 2H, C-4 of acyl), 3.86 and 3.84 (2s, 6H, OMe's), 5 3.95, 3.45, 3.10 (3m, 8H, morpholino and C-2'), 2.38 (t, 2H, C-2 of acyl), 1.92 (m, 2H, C-3 of acyl).


The invention having been fully described, modifications thereof may be apparent to those of ordinary skill in the art. Such modifications are within 10 the scope of the invention as defined by the appended claims.

The invention claimed is:

CLAIMS

1. A compound having the formula:

5



wherein:

R₁ is a terminally substituted normal alkyl having from 1 to 7 carbon atoms, a terminally substituted alkenyl having from 2 to 7 carbon atoms, a terminally substituted ether having from 2 to 6 carbon atoms, a terminally substituted secondary amine having from 2 to 6 carbon atoms, or substituted aryl having less than 8 carbons, where said terminal group is NH₂, substituted amino, acyloxy, SO₃H, PO₄H₂, NNO(OH), SO₂NH₂, PO(OH)NH₂, SO₂R or COOR, where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl, benzyl, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is NH₂ or 10 a substituted amino where the substituents on the amino have 1 to 6 carbon atoms, one of which can be replaced by 15 an oxygen atom or nitrogen atom;

Z is C, CH, or N;

20

R₂ is an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms when Z is C, R₂ is a halogen, NO, amino, or substituted amino when Z is CH, or R₂ is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms when Z is N;

25

A is CO when Z is N, or CR₅ when Z is C or CH, where R₅ is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, aryl or aralkyl having less than 7 carbon atoms, OH, or an O-alkyl having from 1 to 5 carbon atoms

30


and there is a double bond between Z and A when Z is C and a single bond between Z and A when Z is CH;

Y₁ is N, NR₆ or CR₆, where R₆ is H, NO, an amino, a substituted amino, an alkyl, a cyclic alkyl, a 5 heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms;

Y₂ is N or CH; and

X is S when Y₁ and Y₂ are N, CR₇ when Y₁ is NR₆ where R₇ is H, OH, SH, Br, Cl, or I, or =C(R₃)-C(R₄)= when Y₁ is 10 N, CH or CR₆ and Y₂ is N or CH, where each of R₃ and R₄, independently, is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, aryl, alkylcarboxyl, or aralkyl having less than 7 carbon atoms, SH, OH or an O-alkyl having from 1 to 5 carbon atoms,
15 or a salt thereof.

2. The compound of claim 1 having the formula:



R₁ is a terminally substituted normal alkyl having from 1 to 7 carbon atoms, a terminally substituted alkenyl having from 2 to 7 carbon atoms, a terminally substituted ether having from 2 to 6 carbon atoms, a 30

terminally substituted secondary amine having from 2 to 6 carbon atoms, or substituted aryl having less than 8 carbons, where said terminal group is NH_2 , substituted amino, acyloxy, SO_3H , PO_4H_2 , $\text{NNO}(\text{OH})$, SO_2NH_2 , $\text{PO}(\text{OH})\text{NH}_2$,

5 SO_2R or COOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl, benzyl, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is NH_2 or a substituted amino where the substituents on the amino

10 have 1 to 6 carbon atoms, one of which can be replaced by an oxygen atom or nitrogen atom;

R_2 is an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms;

15 each of Y_1 and Y_2 , independently, is N or CH;


each of R_3 and R_4 , independently, is H, SH, OH, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, aryl, alkylcarboxyl, or aralkyl having less than 7 carbon atoms, or OH or an O-alkyl having from 1 to 5 carbon atoms;

R_5 , when present, is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, aryl or aralkyl having less than 7 carbon atoms, OH, or an O-alkyl having from 1 to 5 carbon atoms; and


25 R_6 is NO, an amino, or a substituted amino, or a salt thereof.

3. The compound of claim 2 having the formula:

5



or



wherein

R₁ is a terminally substituted normal alkyl having
 10 from 1 to 7 carbon atoms, a terminally substituted
 alkenyl having from 2 to 7 carbon atoms, a terminally
 substituted ether having from 2 to 6 carbon atoms, a
 terminally substituted secondary amine having from 2 to 6
 carbon atoms, or substituted aryl having less than 8
 15 carbons, where said terminal group is NH₂, substituted
 amino, acyloxy, SO₃H, PO₄H₂, NNO(OH), SO₂NH₂, PO(OH)NH₂,
 SO₂R or COOR where R is H, an alkyl having from 1 to 4
 carbon atoms, an alkenyl having from 1 to 4 carbon atoms,
 tetrazolyl, benzyl, or an alkylamino, where the alkyl
 20 group has from 1 to 4 carbon atoms and the amino is NH₂ or
 a substituted amino where the substituents on the amino
 have 1 to 6 carbon atoms, one of which can be replaced by
 an oxygen atom or nitrogen atom;

R₂, when present, is an alkyl, a cyclic alkyl, a
 25 heterocyclic alkyl, alkenyl, or aralkyl having less than
 7 carbon atoms; and

each of R₃ and R₄, independently, is H, an alkyl, a
 cyclic alkyl, a heterocyclic alkyl, alkenyl, aryl,
 alkylcarboxyl, or aralkyl having less than 7 carbon
 30 atoms, or OH or an O-alkyl having from 1 to 5 carbon
 atoms,

or a salt thereof.

4. The compound of claim 3, wherein R₁ is a terminally substituted normal alkyl having from 1 to 7 carbon atoms, where said terminal group and is NH₂,
 5 substituted amino, or COOR, where R is H, an alkyl having from 1 to 4 carbon atoms, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is a substituted amino where the substituents on the amino have 1 to 6 carbon atoms, one of which can be replaced by
 10 an oxygen atom or nitrogen atom;


R₂, when present, is an alkyl having less than 7 carbon atoms; and

each of R₃ and R₄, independently, is H, an alkyl, aryl, alkylcarboxyl, or aralkyl having less than 7 carbon atoms, or an O-alkyl having from 1 to 5 carbon atoms,
 15

or a salt thereof.

5. The compound of claim 4 having the formula:

20



wherein

R₁ is a terminally substituted normal alkyl having from 1 to 7 carbon atoms where said terminal group is
 25 COOR, where R is H, an alkyl having from 1 to 4 carbon atoms, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is a morpholino group;
 and

each of R₃ and R₄, independently, is H, an alkyl having less than 7 carbon atoms, or an O-alkyl having from 1 to 5 carbon atoms,
 30


or a salt thereof.

6. The compound of claim 5, wherein R₁ is a terminally substituted normal alkyl having from 1 to 4 carbon atoms where said terminal group is COOR where R is an N-morpholinoalkyl group, and each of R₃ and R₄, independently, is an O-alkyl having from 1 to 5 carbon atoms, or a salt thereof.

10 7. The compound of claim 6, wherein R₁ is - (CH₂)₃COOR where R is an N-morpholinoethyl group, and R₃ and R₄ each are methoxy groups, or a salt thereof.

8. The compound of claim 4 having the formula:

15



wherein

20 R₁ is a terminally substituted normal alkyl having from 1 to 7 carbon atoms where said terminal group is COOR, where R is H, an alkyl having from 1 to 4 carbon atoms, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is a morpholino group;

25 R₂ is an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms; and

each of R₃ and R₄, independently, is H, OH, SH, an alkyl, aryl, or aralkyl having less than 7 carbon atoms,

30 or an O-alkyl having from 1 to 5 carbon atoms,

or a salt thereof.


9. The compound of claim 8, wherein R₁ is a terminally substituted normal alkyl having from 1 to 4 5 carbon atoms where said terminal group is COOR where R is an N-morpholinoalkyl group, and R₂ is an alkyl having less than 7 carbon atoms, and each of R₃ and R₄, independently, is H, an alkyl, aryl, or alkylcarboxyl having less than 7 carbon atoms, or an O-alkyl having from 1 to 5 carbon 10 atoms, or a salt thereof.

10. The compound of claim 9, wherein R₁ is - (CH₂)₃COOR where R is an N-morpholinoethyl group, and R₂ is an alkyl having less than 4 carbon atoms, and each of 15 R₃ and R₄, independently, is H, an alkyl having 1 to 3 carbon atoms, phenyl, or methylcarboxyl, or a salt thereof.

11. The compound of claim 10, wherein R₂ is 20 - (CH₂)₂CH₃, and R₃ and R₄ each are H, or a salt thereof.

12. A compound having the formula:

25




where Q is a halogen or substituted amino, R₂ is a halogen, NO, an amino, or a substituted amino, R₃ is SH or OH, R₄ is SH or OH, R₅ is H, an alkyl, a cyclic alkyl, a 30 heterocyclic alkyl, alkenyl, aryl or aralkyl having less than 7 carbon atoms, OH, or an O-alkyl having from 1 to 5

carbon atoms, and R₆ is NO, an amino, or a substituted amino, or a salt thereof.

13. The compound of claim 1 having the formula:

5



10 wherein

R₁ is a terminally substituted normal alkyl having from 1 to 7 carbon atoms, a terminally substituted alkenyl having from 2 to 7 carbon atoms, a terminally substituted ether having from 2 to 6 carbon atoms, a terminally substituted secondary amine having from 2 to 6 carbon atoms, or substituted aryl having less than 8 carbons, where said terminal group is NH₂, substituted amino, acyloxy, SO₃H, PO₄H₂, NNO(OH), SO₂NH₂, PO(OH)NH₂, SO₂R or COOR, where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl, benzyl, or an alkylamino, where the alkyl group has from 1 to 4 carbon atoms and the amino is NH₂ or a substituted amino where the substituents on the amino have 1 to 6 carbon atoms, one of which can be replaced by an oxygen atom or nitrogen atom;

R₂ is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms;

Y₂ is N or CH;

30 R₆ is H, an alkyl, a cyclic alkyl, a heterocyclic alkyl, alkenyl, or aralkyl having less than 7 carbon atoms; and

R₇ is H, OH, SH, Br, Cl, or I,
or a salt thereof.

14. The compound of claim 13, wherein R₁ is a
5 terminally substituted normal alkyl having from 1 to 7
carbon atoms, where said terminal group is NH₂,
substituted amino, or COOR, where R is H, an alkyl having
from 1 to 4 carbon atoms, or an alkylamino, where the
alkyl group has from 1 to 4 carbon atoms and the amino is
10 NH₂ or a substituted amino where the substituents on the
amino have 1 to 6 carbon atoms, one of which can be
replaced by an oxygen atom or nitrogen atom;

R₂ is H, or an alkyl having less than 7 carbon
atoms;

15 Y₂ is N or CH;

R₆ is H, or an alkyl having less than 7 carbon
atoms; and

R₇ is H, OH, SH, or Br,
or a salt thereof.

20

15. The compound of claim 14, wherein R₁ is
-(CH₂)₃COOR where R is an N-morpholinoethyl group, or a
salt thereof.

25 16. The compound of claim 1, wherein R₁ is
-(CH₂)₃COOR where R is an N-morpholinoethyl group, or a
salt thereof.

17. A method for treating a ceramide associated
30 condition in a host comprising administering a
therapeutically effective amount of the compound of claim

6 in a physiologically acceptable carrier to the host in an amount and for a time sufficient to provide protection to the host against a ceramide associated condition being experienced in a tissue of the host.

5

18. A method for treating a ceramide associated condition in a host comprising administering a therapeutically effective amount of the compound of claim 10 in a physiologically acceptable carrier to the host in an amount and for a time sufficient to provide protection to the host against a ceramide associated condition being experienced in a tissue of the host.

19. A method for treating a ceramide associated condition in a host comprising administering a therapeutically effective amount of the compound of claim 12 in a physiologically acceptable carrier to the host in an amount and for a time sufficient to provide protection to the host against a ceramide associated condition being experienced in a tissue of the host.

20. The method according to claim 17 wherein the ceramide associated condition is inflammation, fibrosis, cell senescence, apoptosis, radiation dermatitis, 25 sunburn, or UV induced immune suppression in skin.

21. The method according to claim 18 wherein the ceramide associated condition is inflammation, fibrosis, cell senescence, apoptosis, radiation dermatitis, 30 sunburn, or UV induced immune suppression in skin.

22. The method according to claim 19 wherein the ceramide associated condition is inflammation, fibrosis,

cell senescence, apoptosis, radiation dermatitis, sunburn, or UV induced immune suppression in skin.




FIG. 1


 μM CERAMIDE

FIG. 2

FIG. 3




FIG. 4(A)




FIG. 4(B)




FIG. 4(C)




FIG. 4(D)




FIG. 4(E)




FIG. 4(F)




FIG. 4(G)




FIG. 6

INHIBITION OF TYPE Iu PHOSPHODIESTERASE




FIG. 5(a)




FIG. 5(b)




FIG. 7






FIG. 10








FIG. 9

FIG. 11




FIG. 12




FIG. 13





FIG. 14(A)

S45,928-3


3-NITROXOCARBOSTYRIL

 $C_9H_6N_2O_3$ 

S76,334-9

N2DIMMETHYL-3-(3-FLUOROPHENYL)-1-OXO-1234
TETRAHYDRO-4-ISOQUINOLINECARBOXAMIDE $C_{18}H_{17}FN_2O_2$ 


S93,63C-8

3-AMINO-CYANO-7-NITRO-2-PHENYL-1(2H)-
ISOQUINOLONE $C_{15}H_{10}N_4O_3$ 

S76,469-8


2-METHYL-3-(2-OXOPROPYL)-1(2H)-ISOQUINOLINE

CNE

 $C_{13}H_{13}NO_2$ 

S88,370-0

2-(2-HYDROXYETHYL)-1,4-(2H,3H)-ISOQUINOLONE

 $C_{11}H_{11}NO_3$ 

21,493-0




(H)-1234 TETRAHYDRO-3-ISOQUINOLINE
CARBOXYLIC ACID HYDROCHLORIDE $C_{10}H_{11}NO_2$ 

FIG. 14(B)


36,895-4
3-HYDROXYISOQUINOLINE, 99%
 C_9H_7NO




S94,009-7
3-AMINO-4-CYANO-2-HEXYL-7-NITRO-1(2H)-
ISOQUINOLONE
 $C_{16}H_{18}N_4O_3$




S75,699-7
2-BROMO-4-NITRO-6(5H)-PHENANTHRIDINONE
 $C_{13}H_7BrN_2O_3$




S52,626-6
6,7-DIMETHOXY-1(2H)-ISOQUINOLONE
 $C_{11}H_{11}NO_3$




S84,100-5
4-ISOQUINOLINECARBOXYLIC ACID
 $C_{10}H_7NO_2$




15,013-4
1-ISOQUINOLINECARBOXYLIC ACID, 99%
 $C_{10}H_7NO_2$




S76,087-0
 2-(2-(3,4-DIMETHOXYPHENYL)ETHYL)ISOQUINOLINE-1,3
 (2H,4H)-DIONE
 $C_{19}H_{19}NO_4$




S76,473-6
 1,2-DIHYDRO-2-METHYL-1-OXO-3-ISOQUINOLINES
 UTYRIC ACID
 $C_{14}H_{15}NO_3$



29,963-4
 5(5H)-PHENANTHRIDINONE
 $C_{13}H_9NO$



N165-8
 1,8-NAPHTHALIMIDE, 99%
 $C_{12}H_7NO_2$



33,854-0
 3-ISOQUINOLINECARBOXYLIC ACID HYDRATE, 99%
 $C_{10}H_7NO_2$




FIG. 14(C)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/09964

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07D 473/02, 513/04, 471/04; A61K 31/505, 31/52

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN-CAS on line structure search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 5,670,506 A (LEIGH et al.) 23 September 1997, claim 1	1-16
Y,P	US 5,750,575 A (KLEIN et al.) 12 May 1998, column 56	1-16
Y	US 4,931,437 A (FEDI et al.) 05 June 1990, column 3, table 1(c)	1-16

Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
B earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed	*&*	document member of the same patent family

Date of the actual completion of the international search 02 OCTOBER 1998	Date of mailing of the international search report 21 OCT 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer JOHN M FORD Telephone No. (703) 308-1235 

INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/09964

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: 17-19 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
A ceramide associated condition was not meaningful enough to permit a search
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/09964

A. CLASSIFICATION OF SUBJECT MATTER:

US CL : 544/116, 117, 242, 253, 255, 256, 265, 278, 279, 280; 514/080, 081, 233.5, 233.8, 234.2, 234.5, 258, 262

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S. 544/116, 117, 242, 253, 255, 256, 265, 278, 279, 280; 514/080, 081, 233.5, 233.8, 234.2, 234.5, 258, 262.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

PCT Rule 13.2 provides for one compound invention per application. It provides for the first named invention to be considered the elected invention. However, applicants will be permitted to elect which compound invention they wish to have searched or pay the additional fees for more. In addition to one compound invention, applicants may elect one method of use to be examined therewith. PCT Rule 13.3 provides for the determination of lack of unity of invention to be made whether the different compound inventions are in one claim or more than one claim.

Group I The instances in claims 1-16 where X is a carbon value, Y1 and Y2 are nitrogen, and Z is nitrogen. The purines in class 544-sub 264 et seq.

Group II The instances in claims 1-16 where Z is N, and Y1, X and Y2 are carbon values. The bicyclic pyrimidines in class 544-sub 210+.

Group III The instances in claims 1-16 where pteridines are formed in class 544 sub 257+. That would be Z being N, as well as Y1 and Y2, and X being 2 carbons.

Group IV The instances in claims 1-16 where isoquinolines in class 546 sub 139+ are formed. That is where Z, Y1, Y2, are all carbon, and X is two carbons.

Group V The instances in claims 1-16 where pyrimidine fused to a thiadiazole is formed, classified in class 544 sub 254. That is where Z, Y1 and Y2 are all N, and X is S

Claims 20-22 will be examined with which ever group, above, is elected.

The inventions listed as Groups 1-5 do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: There is no central heterocyclic ring core. Applicants have to pick from among the ring atom variables in order to produce a particular ring.

Accordingly, the claims are not so linked by a special technical feature, within the meaning of PCT Rule 13.2, so as to form a single inventive concept.